ID   2AAB_HUMAN              Reviewed;         601 AA.
AC   P30154; A8MY67; B0YJ69; B4DGQ6; B4DK91; B4DWW5; F8W8G1; O75620;
AC   Q8NHV8;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   15-MAR-2017, entry version 167.
DE   RecName: Full=Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform;
DE   AltName: Full=PP2A subunit A isoform PR65-beta;
DE   AltName: Full=PP2A subunit A isoform R1-beta;
GN   Name=PPP2R1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9795170; DOI=10.1016/S0378-1119(98)00350-3;
RA   Baysal B.E., Farr J.E., Goss J.R., Devlin B., Richard C.W. III;
RT   "Genomic organization and precise physical location of protein
RT   phosphatase 2A regulatory subunit A beta isoform gene on chromosome
RT   band 11q23.";
RL   Gene 217:107-116(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-8; SER-65;
RP   ASP-90; PRO-101; GLU-343; ALA-448; GLY-504 AND ALA-545.
RX   PubMed=9765152; DOI=10.1126/science.282.5387.284;
RA   Wang S.S., Esplin E.D., Li J.L., Huang L., Gazdar A., Minna J.,
RA   Evans G.A.;
RT   "Alterations of the PPP2R1B gene in human lung and colon cancer.";
RL   Science 282:284-287(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11313745; DOI=10.1038/sj/ejhg/5200585;
RA   Baysal B.E., Willett-Brozick J.E., Taschner P.E.M., Dauwerse J.G.,
RA   Devilee P., Devlin B.;
RT   "A high-resolution integrated map spanning the SDHD gene at 11q23: a
RT   1.1-Mb BAC contig, a partial transcript map and 15 new repeat
RT   polymorphisms in a tumour-suppressor region.";
RL   Eur. J. Hum. Genet. 9:121-129(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 4 AND 5).
RC   TISSUE=Brain, Testis, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 31-601 (ISOFORM 1).
RX   PubMed=2159327; DOI=10.1021/bi00465a002;
RA   Hemmings B.A., Adams-Pearson C., Maurer F., Mueller P., Goris J.,
RA   Merlevede W., Hofsteenge J., Stone S.R.;
RT   "Alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A
RT   have a similar 39 amino acid repeating structure.";
RL   Biochemistry 29:3166-3173(1990).
RN   [10]
RP   INTERACTION WITH RAF1.
RX   PubMed=10801873; DOI=10.1074/jbc.M003259200;
RA   Abraham D., Podar K., Pacher M., Kubicek M., Welzel N., Hemmings B.A.,
RA   Dilworth S.M., Mischak H., Kolch W., Baccarini M.;
RT   "Raf-1-associated protein phosphatase 2A as a positive regulator of
RT   kinase activation.";
RL   J. Biol. Chem. 275:22300-22304(2000).
RN   [11]
RP   INTERACTION WITH IPO9.
RX   PubMed=12670497; DOI=10.1016/S0006-291X(03)00434-0;
RA   Lubert E.J., Sarge K.D.;
RT   "Interaction between protein phosphatase 2A and members of the
RT   importin beta superfamily.";
RL   Biochem. Biophys. Res. Commun. 303:908-913(2003).
RN   [12]
RP   INTERACTION WITH SGO1.
RX   PubMed=16541025; DOI=10.1038/nature04663;
RA   Kitajima T.S., Sakuno T., Ishiguro K., Iemura S., Natsume T.,
RA   Kawashima S.A., Watanabe Y.;
RT   "Shugoshin collaborates with protein phosphatase 2A to protect
RT   cohesin.";
RL   Nature 441:46-52(2006).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   VARIANT ASP-90.
RX   PubMed=10597236; DOI=10.1038/sj.onc.1203070;
RA   Campbell I.G., Manolitsas T.;
RT   "Absence of PPP2R1B gene alterations in primary ovarian cancers.";
RL   Oncogene 18:6367-6369(1999).
RN   [17]
RP   VARIANTS ALA-15; PRO-365; GLU-498; ILE-499 AND GLY-500.
RX   PubMed=10896920; DOI=10.1136/gut.47.2.268;
RA   Takagi Y., Futamura M., Yamaguchi K., Aoki S., Takahashi T., Saji S.;
RT   "Alterations of the PPP2R1B gene located at 11q23 in human colorectal
RT   cancers.";
RL   Gut 47:268-271(2000).
RN   [18]
RP   VARIANT ASP-90.
RX   PubMed=11996789; DOI=10.1016/S0165-4608(01)00597-0;
RA   Hemmer S., Wasenius V.M., Haglund C., Zhu Y., Knuutila S.,
RA   Franssila K., Joensuu H.;
RT   "Alterations in the suppressor gene PPP2R1B in parathyroid
RT   hyperplasias and adenomas.";
RL   Cancer Genet. Cytogenet. 134:13-17(2002).
CC   -!- FUNCTION: The PR65 subunit of protein phosphatase 2A serves as a
CC       scaffolding molecule to coordinate the assembly of the catalytic
CC       subunit and a variable regulatory B subunit.
CC   -!- SUBUNIT: PP2A consists of a common heterodimeric core enzyme,
CC       composed of a 36 kDa catalytic subunit (subunit C) and a 65 kDa
CC       constant regulatory subunit (PR65 or subunit A), that associates
CC       with a variety of regulatory subunits. Proteins that associate
CC       with the core dimer include three families of regulatory subunits
CC       B (the R2/B/PR55/B55, R3/B''/PR72/PR130/PR59 and R5/B'/B56
CC       families), the 48 kDa variable regulatory subunit, viral proteins,
CC       and cell signaling molecules. Interacts with IPO9. Interacts with
CC       SGO1. Interacts with RAF1. {ECO:0000269|PubMed:10801873,
CC       ECO:0000269|PubMed:12670497, ECO:0000269|PubMed:16541025}.
CC   -!- INTERACTION:
CC       O08785:Clock (xeno); NbExp=2; IntAct=EBI-357094, EBI-79859;
CC       P67775:PPP2CA; NbExp=7; IntAct=EBI-357094, EBI-712311;
CC       P30153:PPP2R1A; NbExp=2; IntAct=EBI-357094, EBI-302388;
CC       P63151:PPP2R2A; NbExp=3; IntAct=EBI-357094, EBI-1048931;
CC       Q15172:PPP2R5A; NbExp=2; IntAct=EBI-357094, EBI-641666;
CC       Q13362:PPP2R5C; NbExp=2; IntAct=EBI-357094, EBI-1266156;
CC       Q14738:PPP2R5D; NbExp=3; IntAct=EBI-357094, EBI-396563;
CC       Q16537:PPP2R5E; NbExp=3; IntAct=EBI-357094, EBI-968374;
CC       P11233:RALA; NbExp=6; IntAct=EBI-357094, EBI-1036803;
CC       O08722:Unc5b (xeno); NbExp=4; IntAct=EBI-357094, EBI-4404185;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=P30154-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P30154-2; Sequence=VSP_036460;
CC       Name=3;
CC         IsoId=P30154-3; Sequence=VSP_043379, VSP_036460;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=P30154-4; Sequence=VSP_045275;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=P30154-5; Sequence=VSP_046684;
CC   -!- DOMAIN: Each HEAT repeat appears to consist of two alpha helices
CC       joined by a hydrophilic region, the intrarepeat loop. The repeat
CC       units may be arranged laterally to form a rod-like structure.
CC   -!- SIMILARITY: Belongs to the phosphatase 2A regulatory subunit A
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA59983.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=BAG59103.1; Type=Frameshift; Positions=540; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF083439; AAC63525.1; -; Genomic_DNA.
DR   EMBL; AF083425; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083426; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083427; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083428; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083429; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083430; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083431; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083432; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083433; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083434; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083435; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083436; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083437; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF083438; AAC63525.1; JOINED; Genomic_DNA.
DR   EMBL; AF087438; AAC69624.1; -; mRNA.
DR   EMBL; AF163473; AAG39644.1; -; mRNA.
DR   EMBL; AK294716; BAG57867.1; -; mRNA.
DR   EMBL; AK296455; BAG59103.1; ALT_FRAME; mRNA.
DR   EMBL; AK301705; BAG63177.1; -; mRNA.
DR   EMBL; EF445011; ACA06046.1; -; Genomic_DNA.
DR   EMBL; EF445011; ACA06047.1; -; Genomic_DNA.
DR   EMBL; AP000925; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67150.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67151.1; -; Genomic_DNA.
DR   EMBL; BC027596; AAH27596.1; -; mRNA.
DR   EMBL; M65254; AAA59983.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS53706.1; -. [P30154-3]
DR   CCDS; CCDS53707.1; -. [P30154-5]
DR   CCDS; CCDS53708.1; -. [P30154-4]
DR   CCDS; CCDS8348.1; -. [P30154-2]
DR   CCDS; CCDS8349.1; -. [P30154-1]
DR   PIR; B34541; B34541.
DR   RefSeq; NP_001171033.1; NM_001177562.1. [P30154-4]
DR   RefSeq; NP_001171034.1; NM_001177563.1. [P30154-5]
DR   RefSeq; NP_002707.3; NM_002716.4. [P30154-1]
DR   RefSeq; NP_859050.1; NM_181699.2. [P30154-2]
DR   RefSeq; NP_859051.1; NM_181700.1. [P30154-3]
DR   UniGene; Hs.269128; -.
DR   UniGene; Hs.584790; -.
DR   ProteinModelPortal; P30154; -.
DR   SMR; P30154; -.
DR   BioGrid; 111511; 109.
DR   DIP; DIP-36616N; -.
DR   IntAct; P30154; 78.
DR   MINT; MINT-1150161; -.
DR   STRING; 9606.ENSP00000311344; -.
DR   iPTMnet; P30154; -.
DR   PhosphoSitePlus; P30154; -.
DR   BioMuta; PPP2R1B; -.
DR   DMDM; 116241236; -.
DR   EPD; P30154; -.
DR   MaxQB; P30154; -.
DR   PaxDb; P30154; -.
DR   PeptideAtlas; P30154; -.
DR   PRIDE; P30154; -.
DR   DNASU; 5519; -.
DR   Ensembl; ENST00000311129; ENSP00000311344; ENSG00000137713. [P30154-2]
DR   Ensembl; ENST00000341980; ENSP00000343317; ENSG00000137713. [P30154-4]
DR   Ensembl; ENST00000393055; ENSP00000376775; ENSG00000137713. [P30154-5]
DR   Ensembl; ENST00000426998; ENSP00000410671; ENSG00000137713. [P30154-3]
DR   Ensembl; ENST00000527614; ENSP00000437193; ENSG00000137713. [P30154-1]
DR   GeneID; 5519; -.
DR   KEGG; hsa:5519; -.
DR   UCSC; uc001plw.2; human. [P30154-1]
DR   CTD; 5519; -.
DR   DisGeNET; 5519; -.
DR   GeneCards; PPP2R1B; -.
DR   HGNC; HGNC:9303; PPP2R1B.
DR   HPA; CAB004034; -.
DR   HPA; HPA018908; -.
DR   MalaCards; PPP2R1B; -.
DR   MIM; 603113; gene.
DR   neXtProt; NX_P30154; -.
DR   OpenTargets; ENSG00000137713; -.
DR   PharmGKB; PA33667; -.
DR   eggNOG; KOG0211; Eukaryota.
DR   eggNOG; ENOG410XQVI; LUCA.
DR   GeneTree; ENSGT00730000110944; -.
DR   HOGENOM; HOG000078539; -.
DR   HOVERGEN; HBG000011; -.
DR   InParanoid; P30154; -.
DR   KO; K03456; -.
DR   OMA; CGREITT; -.
DR   OrthoDB; EOG091G045V; -.
DR   PhylomeDB; P30154; -.
DR   TreeFam; TF105552; -.
DR   Reactome; R-HSA-113501; Inhibition of replication initiation of damaged DNA by RB1/E2F1.
DR   Reactome; R-HSA-163685; Integration of energy metabolism.
DR   Reactome; R-HSA-163767; PP2A-mediated dephosphorylation of key metabolic factors.
DR   Reactome; R-HSA-180024; DARPP-32 events.
DR   Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex.
DR   Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-202670; ERKs are inactivated.
DR   Reactome; R-HSA-2465910; MASTL Facilitates Mitotic Progression.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-432142; Platelet sensitization by LDL.
DR   Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; R-HSA-5339716; Misspliced GSK3beta mutants stabilize beta-catenin.
DR   Reactome; R-HSA-5358747; S33 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; R-HSA-5358749; S37 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; R-HSA-5358751; S45 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; R-HSA-5358752; T41 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; R-HSA-5467337; APC truncation mutants have impaired AXIN binding.
DR   Reactome; R-HSA-5467340; AXIN missense mutants destabilize the destruction complex.
DR   Reactome; R-HSA-5467348; Truncations of AMER1 destabilize the destruction complex.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-68877; Mitotic Prometaphase.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-69273; Cyclin A/B1 associated events during G2/M transition.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   SIGNOR; P30154; -.
DR   ChiTaRS; PPP2R1B; human.
DR   GeneWiki; PPP2R1B; -.
DR   GenomeRNAi; 5519; -.
DR   PRO; PR:P30154; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000137713; -.
DR   CleanEx; HS_PPP2R1B; -.
DR   ExpressionAtlas; P30154; baseline and differential.
DR   Genevisible; P30154; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0060561; P:apoptotic process involved in morphogenesis; IMP:UniProtKB.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000357; HEAT.
DR   InterPro; IPR021133; HEAT_type_2.
DR   Pfam; PF02985; HEAT; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   PROSITE; PS50077; HEAT_REPEAT; 12.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Complete proteome; Polymorphism;
KW   Reference proteome; Repeat.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    601       Serine/threonine-protein phosphatase 2A
FT                                65 kDa regulatory subunit A beta isoform.
FT                                /FTId=PRO_0000071403.
FT   REPEAT       20     58       HEAT 1.
FT   REPEAT       59     96       HEAT 2.
FT   REPEAT       97    135       HEAT 3.
FT   REPEAT      136    173       HEAT 4.
FT   REPEAT      174    212       HEAT 5.
FT   REPEAT      213    251       HEAT 6.
FT   REPEAT      252    290       HEAT 7.
FT   REPEAT      291    333       HEAT 8.
FT   REPEAT      334    372       HEAT 9.
FT   REPEAT      373    411       HEAT 10.
FT   REPEAT      412    450       HEAT 11.
FT   REPEAT      451    489       HEAT 12.
FT   REPEAT      490    528       HEAT 13.
FT   REPEAT      529    567       HEAT 14.
FT   REPEAT      568    601       HEAT 15.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   VAR_SEQ      39    102       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043379.
FT   VAR_SEQ     103    229       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046684.
FT   VAR_SEQ     344    388       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045275.
FT   VAR_SEQ     598    601       LALA -> VAQRLRKLEFPVKDSGEPSVPRADKNHFPRPTV
FT                                PGEDMGKGPVYQLRGDTRDTLAQLGIAELVHFSQSTD (in
FT                                isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_036460.
FT   VARIANT       8      8       G -> R (in a lung cancer patient;
FT                                dbSNP:rs142771326).
FT                                {ECO:0000269|PubMed:9765152}.
FT                                /FTId=VAR_022895.
FT   VARIANT      15     15       G -> A (in a colorectal cancer patient).
FT                                {ECO:0000269|PubMed:10896920}.
FT                                /FTId=VAR_022896.
FT   VARIANT      65     65       P -> S (in a lung cancer patient).
FT                                {ECO:0000269|PubMed:9765152}.
FT                                /FTId=VAR_022897.
FT   VARIANT      90     90       G -> D (in a lung cancer patient;
FT                                dbSNP:rs1805076).
FT                                {ECO:0000269|PubMed:10597236,
FT                                ECO:0000269|PubMed:11996789,
FT                                ECO:0000269|PubMed:9765152}.
FT                                /FTId=VAR_006384.
FT   VARIANT     101    101       L -> P (in a colon adenocarcinoma).
FT                                {ECO:0000269|PubMed:9765152}.
FT                                /FTId=VAR_022898.
FT   VARIANT     343    343       K -> E (in a lung cancer patient).
FT                                {ECO:0000269|PubMed:9765152}.
FT                                /FTId=VAR_022899.
FT   VARIANT     365    365       S -> P (in a colorectal cancer patient).
FT                                {ECO:0000269|PubMed:10896920}.
FT                                /FTId=VAR_022900.
FT   VARIANT     448    448       V -> A (in a colon adenocarcinoma).
FT                                {ECO:0000269|PubMed:9765152}.
FT                                /FTId=VAR_022901.
FT   VARIANT     498    498       V -> E (in a colorectal cancer patient).
FT                                {ECO:0000269|PubMed:10896920}.
FT                                /FTId=VAR_022902.
FT   VARIANT     499    499       L -> I (in a colorectal cancer patient).
FT                                {ECO:0000269|PubMed:10896920}.
FT                                /FTId=VAR_022903.
FT   VARIANT     500    500       V -> G (in a colorectal cancer patient).
FT                                {ECO:0000269|PubMed:10896920}.
FT                                /FTId=VAR_022904.
FT   VARIANT     504    504       D -> G (in a lung cancer patient).
FT                                {ECO:0000269|PubMed:9765152}.
FT                                /FTId=VAR_022905.
FT   VARIANT     545    545       V -> A (in a colon adenocarcinoma).
FT                                {ECO:0000269|PubMed:9765152}.
FT                                /FTId=VAR_022906.
FT   CONFLICT     74     74       E -> V (in Ref. 9; AAA59983).
FT                                {ECO:0000305}.
FT   CONFLICT    178    178       I -> T (in Ref. 1; AAC63525, 3; AAG39644
FT                                and 9; AAA59983). {ECO:0000305}.
FT   CONFLICT    211    211       D -> G (in Ref. 4; BAG57867).
FT                                {ECO:0000305}.
FT   CONFLICT    411    411       Q -> R (in Ref. 9; AAA59983).
FT                                {ECO:0000305}.
FT   CONFLICT    503    503       N -> S (in Ref. 4; BAG57867).
FT                                {ECO:0000305}.
SQ   SEQUENCE   601 AA;  66214 MW;  86AB20D7505210B0 CRC64;
     MAGASELGTG PGAAGGDGDD SLYPIAVLID ELRNEDVQLR LNSIKKLSTI ALALGVERTR
     SELLPFLTDT IYDEDEVLLA LAEQLGNFTG LVGGPDFAHC LLPPLENLAT VEETVVRDKA
     VESLRQISQE HTPVALEAYF VPLVKRLASG DWFTSRTSAC GLFSVCYPRA SNAVKAEIRQ
     QFRSLCSDDT PMVRRAAASK LGEFAKVLEL DSVKSEIVPL FTSLASDEQD SVRLLAVEAC
     VSIAQLLSQD DLETLVMPTL RQAAEDKSWR VRYMVADRFS ELQKAMGPKI TLNDLIPAFQ
     NLLKDCEAEV RAAAAHKVKE LGENLPIEDR ETIIMNQILP YIKELVSDTN QHVKSALASV
     IMGLSTILGK ENTIEHLLPL FLAQLKDECP DVRLNIISNL DCVNEVIGIR QLSQSLLPAI
     VELAEDAKWR VRLAIIEYMP LLAGQLGVEF FDEKLNSLCM AWLVDHVYAI REAATNNLMK
     LVQKFGTEWA QNTIVPKVLV MANDPNYLHR MTTLFCINAL SEACGQEITT KQMLPIVLKM
     AGDQVANVRF NVAKSLQKIG PILDTNALQG EVKPVLQKLG QDEDMDVKYF AQEAISVLAL
     A
//
